Site Editor

Leo I. Gordon, MD, FACP

Advertisement
Advertisement

Updated Trial Data on Tazemetostat-Based Regimen in Follicular Lymphoma

By: Vanessa A. Carter, BS
Posted: Thursday, July 7, 2022

In a phase Ib study, Connie Lee Batlevi, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues evaluated the use of tazemetostat—an enhancer zeste homolog 2 (EZH2) inhibitor—in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma. During the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 7572), the study authors presented their latest results from this updated interim analysis.

“In clinical studies in patients with relapsed/refractory follicular lymphoma, lenalidomide and rituximab demonstrated an objective response rate of 73% to 78% and median progression-free survival of 36 to 39 months,” mentioned the investigators. “[The] tazemetostat plus lenalidomide and rituximab combination demonstrates consistent and unaltered pharmacokinetics for tazemetostat and lenalidomide as well as a favorable safety profile and efficacy trend.”

The researchers enrolled 43 patients with relapsed or refractory follicular lymphoma who received at least one priory therapy. Participants were randomly assigned to receive tazemetostat at dose levels of 400 mg (n = 4), 600 mg (n = 18), and 800 mg (n = 21), along with standard doses of lenalidomide and rituximab.

The median patient age was 67, and patients received a median of one prior therapy. Just over one-third of participants were refractory to rituximab, and six individuals had mutant-type EZH2. The median duration of treatment was 32 weeks, and the median progression-free survival and overall duration of response were not reached at the median follow-up of 5.8 months. The objective response rate was 94.7%, consisting of 19 complete responses, 17 partial responses, and 2 cases of stable disease.

A total of 14 patients experienced serious treatment-emergent adverse events, and grade 3 or 4 events were reported in 24 participants. Of note, the most common grade 3 or 4 treatment-emergent adverse event was a decrease in neutrophil count (n = 13). Of note, no dose-limiting toxicities or new safety signals were observed at data cutoff.

Disclosure: For full disclosures of the study authors, visit coi.asco.org.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.